Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:30:17 2023-02-07 am EST
79.30 CHF   +0.19%
05:04aNOVARTIS AG : Deutsche Bank gives a Sell rating
MD
02/06NOVARTIS AG : Berenberg reaffirms its Neutral rating
MD
02/06Novartis : ESG Update Q4 2022
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Oddo gives a Buy rating

06/22/2020 | 05:54am EST

Oddo is positive on the stock with a Buy rating. The target price differs slightly and is now set at CHF 97 versus CHF 96.


ę MarketScreener with dpa-AFX Analyser 2020
All news about NOVARTIS AG
05:04aNOVARTIS AG : Deutsche Bank gives a Sell rating
MD
02/06NOVARTIS AG : Berenberg reaffirms its Neutral rating
MD
02/06Novartis : ESG Update Q4 2022
PU
02/06Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro..
AQ
02/06Novartis' Sandoz Unit Says US FDA Accepted Biologics License Application for Osteoporos..
MT
02/06Novartis Says Sandoz's Prolia, Xgeva Biosimilar Accepted for Review in US
MT
02/06Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US F..
GL
02/06Novartis : Sandoz Biologics License Application for proposed biosimilar denosum..
DJ
02/05Novartis' Cosentyx Continues to Improve Symptom at One Year in Late-stage Skin Disease ..
MT
02/03Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro..
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2023 52 275 M - -
Net income 2023 9 640 M - -
Net Debt 2023 13 850 M - -
P/E ratio 2023 18,6x
Yield 2023 4,04%
Capitalization 182 B 182 B -
EV / Sales 2023 3,75x
EV / Sales 2024 3,57x
Nbr of Employees 102 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 85,86 $
Average target price 97,17 $
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-5.31%180 893
JOHNSON & JOHNSON-6.82%427 102
ELI LILLY AND COMPANY-7.31%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-6.24%263 757